A judge has ruled that Texas Governor Greg Abbott’s executive order banning mask mandates in schools is a violation of federal law. The ruling said that the order violates the Americans with Disabilities Act, as children with special health needs are particularly vulnerable to COVID-19. (CNBC Weekly)

Cortexyme plans to push forward with its Alzheimer’s drug atuzaginstat despite its failure in a mid-stage trial. Data presented Thursday suggested atuzaginstat did not perform better than a placebo at slowing cognitive decline. (STAT)

The Food and Drug Administration has recalled two million Ellume at-home COVID-19 tests due to false positive results. The company issued a voluntary recall in October due to the same issue. (Business Insider)

Much research on COVID-19 vaccine efficacy shows that Pfizer and Moderna vaccines remain highly protective months after inoculation. But new data suggest that protection may gradually wane over time. (The New York Times)

List Biotherapeutics is investing $125 million in an expansion of new manufacturing operations. The investment includes a 110,000-square-foot facility and the hiring of 210 new employees. (Endpoints News)